Journals / Phoenix Medical Journal / 2021 / Cilt: 3 Sayı: 2

Evaluation of Myocardial Damage in Relation to HbA1c in Patients with Previously Unrecognized Diabetes Presenting with STEMI

STEMI ile Başvuran Önceden Tanı Almamış Diyabetli Hastalarda HbA1c ile İlişkili Miyokard Hasarının Değerlendirilmesi

Pages
59–63
Publication Date
2021-07-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies assessing the effects of other factors unrelated to chronic glucose control on myocardial damage and cardiovascular event rates in these patients would be of great interest.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The mechanisms underlying worse clinical outcomes in previously unrecognized diabetic (DM) patients in ST-elevation myocardial infarction (STEMI) are unclear.
📊
Key Findings & Data:Material and Method: 51 newly diagnosed DM patients with glycated hemoglobin A1c (HbA1c) > 6.5 comprised the DM group, 54 sex- and age-matched individuals with normal glucose metabolism served as the non-DM group.
💡
Conclusion & Impact:Future studies assessing the effects of other factors unrelated to chronic glucose control on myocardial damage and cardiovascular event rates in these patients would be of great interest.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akut koroner sendrom · kardiyak belirteçler · diabetes mellitus

Abstract

Objective: The mechanisms underlying worse clinical outcomes in previously unrecognized diabetic (DM) patients in ST-elevation myocardial infarction (STEMI) are unclear. It was hypothesized that poor chronic glucose control might be related to greater myocardial damage. Material and Method: 51 newly diagnosed DM patients with glycated hemoglobin A1c (HbA1c) > 6.5 comprised the DM group, 54 sex- and age-matched individuals with normal glucose metabolism served as the non-DM group. Each patient underwent primary angioplasty for STEMI. The levels of cardiac specific markers before angioplasty, during angioplasty, at 6, 12, and 18 h after angioplasty were recorded. SPSS 10 package program was used to analyse data. Results: In both DM and non-DM groups troponin peaked at 6 h. Peak troponin levels were similar in both groups (diabetics, 22.89 ± 18.19 vs. non-diabetics, 32.67 ± 17.68 ng/ml, p=0.168). Conclusions: HbA1c > 6.5 is not related to extent of infarction in previously unrecognized DM patients presenting with STEMI. Future studies assessing the effects of other factors unrelated to chronic glucose control on myocardial damage and cardiovascular event rates in these patients would be of great interest.

Özet

Amaç: Daha önce tanısı konulmamış diyabetik hastalarda ST elevasyonlu miyokard enfarktüsünde (STEMI) kötü klinik sonuçların altında yatan mekanizmalar belirsizdir. Kötü glisemik kontrolün daha büyük miyokard hasarı ile ilişkili olabileceği hipotezi oluşturulmuştur. Gereç ve Yöntem: Glikolize hemoglobin A1c (HbA1c)> 6.5 olan yeni tanı konmuş 51 DM hastası DM grubunu, normal glikoz metabolizması olan 54 cinsiyet ve yaş eşleşmeli birey DM olmayan grup olarak çalışmaya dahil edildi. Her hastaya STEMI için primer anjiyoplasti yapıldı. Anjiyoplasti öncesi, anjiyoplasti sırasında, anjiyoplastiden 6, 12 ve 18 saat sonra kardiyak spesifik belirteç seviyeleri kaydedildi. Veriler SPSS 10 paket program eşliğinde analiz edildi. Bulgular: Hem DM hem de DM olmayan gruplarda troponin 6. saatte zirve yaptı. Pik troponin düzeyleri her iki grupta da benzerdi (diyabetliler, 22.89 ± 18.19 ve nondiyabetikler, 32.67 ± 17.68 ng / ml, p = 0.168). Sonuç: HbA1c’nin 6,5’tan büyük olması, STEMI ile başvuran ve daha önce DM tanısı olmayan hastalarda infarkt alanının genişliği bakımından fark bulunmamıştır. Bu hastalarda miyokard hasarı ve kardiyovasküler olay oranlarını etkileyecek kronik glikoz kontrolü dışında faktörleri değerlendirmek için gelecek çalışmalara ihtiyaç vardır.

🔖

Cite This Article

ASLAN, O., YAYLALI, Y. T., YURTDAŞ, M., YAYLALI, G. F., AYBEK, H., YILDIRIM, S. (2021). Evaluation of Myocardial Damage in Relation to HbA1c in Patients with Previously Unrecognized Diabetes Presenting with STEMI. Phoenix Medical Journal, Cilt: 3 Sayı: 2, 59–63. https://ajindex.com/articles/937049

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. McGuire DK. Diabetes and the cardiovascular system. in: Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald’s heart disease. 9th ed. Elsevier Saunders, Philadelphia 2012:1392-1409.
  2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025:prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431.
  3. Gholap N, Davies MJ, Mostafa SA, Squire I, Khunti K. A simple strategy for screening for glucose intolerance, using glycated haemoglobin, in individuals admitted with acute coronary syndrome. Diabet Med 2012;29:838-843.
  4. Arruda-Olson AM, Roger VL, Jaffe AS, Hodge DO, Gibbons RJ, Miller TD. Troponin T levels and infarct size by SPECT myocardial perfusion imaging. JACC: Cardiovasc Imaging 2011;4:523-533.
  5. Gustafsson I, Kistorp CN, James MK, Faber JO, Dickstein K, Hildebrandt PR. Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. Am Heart J 2007;154:470-476.
  6. Hermanides RS, Kennedy MW, Kedhi E, van Dijk PR, Timmer JR, Ottervanger JP, at al. Impact of elevated HbA1c on long-term mortality in patients presenting with acute myocardial infarction in daily clinical practice: insights from a ‘real world’prospective registry of the Zwolle Myocardial Infarction Study Group. Eur Heart J Acute Cardiovasc Care. 2020 Sep;9(6):616-625.
  7. Cherneva ZV, Denchev SV, Gospodinova MV, Milcheva NP, Petrova MG, Cherneva RV. Clinical significance of hyperglycaemia in acute coronary syndrome patients. Acute Card Care 2011;13:211-218.
  8. Chan CY, Li R, Chan JY, Zhang Q, Chan CP, Dong M, et al. The value of admission HbA(1c) level in diabetic patients with acute coronary syndrome. Clin Cardiol 2011;34:507-512.
  9. Tian L, Zhu J, Liu L, Liang Y, Li J, Yang Y. Hemoglobin A1c and short-term outcomes in patients with acute myocardial infarction undergoing primary angioplasty: an observational multicenter study. Coron Artery Dis 2013;24:16-22.
  10. Hage C, Lundman P, Rydén L, Mellbin L. Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes. Eur J Prev Cardiol 2013;20:549-554. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37 Suppl 1:S62-69. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20:457-464.
  11. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral